VEO Ophthalmics’ Artificial Iris, Boston Scientific’s Single-Use Duodenoscope Win Pass-Through Payments
Executive Summary
US CMS described several products winning device pass-through payment status for 2021 in an outpatient prospective payment system final rule.
You may also be interested in...
CVRx Raises $75M In IPO To Commercialize And Develop Heart Failure Therapy
The funds will support expanded commercialization of the company’s baroreflex activation stimulation technology to treat heart failure in patients with a low left-ventricular ejection fraction.
CMS Proposes Extra Payments On CustomFlex Iris, Single-Use Duodenoscope, Heart Device
The Centers for Medicare and Medicaid Services highlighted three FDA breakthrough devices it is proposing for additional pass-through payments in its 2021 outpatient pay rule.
‘Right Product, Right Time:’ FDA Clears Boston Scientific's Single-Use Duodenoscope
Amid concerns of infections from duodenoscopes that are not sufficiently re-sterilized, the US FDA has cleared Boston Scientific’s Exalt-D as a the first single-use duodenoscope. Investors expect the device will likely take a significant chunk of the market, especially considering the next competitor is at least a year away.